Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials

Clinical Trials

Volumn 11, Issue 5, 2014, Pages 553-559

  Rosas, Scott R ^a   Schouten, Jeffrey T ^b   Dixon, Dennis ^c   Varghese, Suresh ^d   Cope, Marie T ^a   Marci, Joe ^e   Kagan, Jonathan M ^e  

^a Department of Research   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Digital Infuzion Inc ^*  (United States)

^d Digital Infuzion   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

HIV AIDS clinical trials; Protocol development; Protocol implementation; Survival analysis; Time based analyses

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; EVALUATION STUDY; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIORITY JOURNAL; TIME; ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV INFECTIONS; KAPLAN MEIER METHOD; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; PATIENT SELECTION; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; BIOMEDICAL RESEARCH; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); PATIENT SELECTION; TIME FACTORS; UNITED STATES;

EID: 84927713337     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774514540814     Document Type: Article

References (20)

1. Getz KA, Wenger J, Campo RA, et al. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15(5): 450-457.
2. Cheng SK, Dietrich MS and Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res 2010; 16(22): 5557-5563.
3. Getz K. Protocol design trends and their effect on clinical trial performance. RAJ Pharma, May 2008, pp. 315-316.
4. Kaitin KI (ed.). Growing protocol design complexity stresses investigators, volunteers. Tufts Center for the Study of Drug Development Impact Report. January-February 2008, vol. 10, No.1., http://csdd.tufts.edu/files/uploads/jan-feb-impact-report-summary.pdf
5. Kitterman DR, Cheng SK, Dilts DM, et al. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med 2011; 86(11): 1360-1366.
6. Wang-Gillam A, Williams K, Novello S, et al. Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the Atlantic. J Clin Oncol 2010; 28(24): 3803-3807.
7. Dilts DM and Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006; 24(28): 4545-4552.
8. Dilts DM, Cheng SK, Crites JS, et al. Phase III clinical trial development: a process of chutes and ladders. Clin Cancer Res 2010; 16(22): 5381-5389.
9. Getz KA. The heavy burden of protocol design. Appl Clin Trials 2008; 17(3): 38-40.
10. Dilts DM, Sandler AB, Cheng SK, et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 2009; 27(11): 1761-1766.
11. Dilts DM, Sandler AB, Baker M, et al. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the case of Cancer and Leukemia Group B. J Clin Oncol 2006; 24(28): 4553-4557.
12. Kagan JM, Kane M, Quinlan KM, et al. Developing a conceptual framework for an evaluation system for the NIAID HIV/AIDS clinical trials networks. Health Res Policy Syst 2009; 7: 12.
13. Kagan JM, Rosas S and Trochim WMK. Integrating utilization-focused evaluation with business process modeling for clinical research improvement. Res Eval 2010; 19(4): 239-250.
14. Kagan JM, Gupta N, Varghese S, et al. The NIAID Division of AIDS enterprise information system: integrated decision support for global clinical research programs. J Am Med Inform Assoc 2011; 18(Suppl. 1): i161-165.
15. Cheng SK, Dietrich MS and Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clin Cancer Res 2011; 17(7): 1947-1955.
16. McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006; 7(1): 9.
17. Dilts DM, Rosenblum D and Trochim WM. A virtual national laboratory for reengineering clinical translational science. Sci Transl Med 2012; 4(118): 118cm2.
18. Trochim W, Kane C, Graham MJ, et al. Evaluating translational research: a process marker model. Clin Transl Sci 2011; 4(3): 153-162.
19. McJoynt TA, Hirzallah MA, Satele DV, et al. Building a protocol expressway: the case of Mayo Clinic Cancer Center. J Clin Oncol 2009; 27(23): 3855-3860.
20. Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials 2008; 5(1): 75-84.